Beta Biosciences, LLC

Beta Biosciences, LLC was paid $55K by Medicaid between Aug 2020 and May 2024, across 35 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 87% of everything it billed.

33Billing provider infoBETA BIOSCIENCES, LLC
KANSAS CITY, MO 64118

33aNPI1245692169assigned 03/22/2016

33bProvider typeClinical Medical Laboratory

28Total paid$55K

24GClaims5,325

24DCodes billed35

24AFirst – last monthAug 2020 – May 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in Missouri

Rank by total paid#36 of 61

Median peer was paid$85K

This provider vs. median0.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	738	$31K
2021	4,127	$23K
2024incomplete	460	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	87%	2,054	1,262	$48K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.8%	1,347	710	$3K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.8%	261	214	$3K
82610		<1%	25	24	$155.60
86800		<1%	25	24	$120.24
82670		<1%	12	12	$117.35
80061	Lipid panel	<1%	26	25	$112.50
84466		<1%	25	24	$107.20
83036	Hemoglobin; glycosylated (A1C)	<1%	26	25	$73.44
84481		<1%	13	13	$71.15
82607		<1%	13	13	$63.35
82746		<1%	12	12	$61.75

23 more codes

86376		<1%	12	$61.10
82977		<1%	25	$60.50
86141		<1%	14	$54.40
84443	Thyroid stimulating hormone (TSH)	<1%	12	$53.76
80053	Comprehensive metabolic panel	<1%	15	$50.64
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	16	$43.47
82172		<1%	25	$35.44
85045		<1%	25	$33.50
83690		<1%	14	$28.95
84436		<1%	12	$28.85
83735		<1%	14	$28.15
82150		<1%	14	$27.20
84479		<1%	13	$27.15
83540		<1%	14	$27.15
83615		<1%	14	$25.35
86431		<1%	14	$23.80
82248		<1%	14	$21.10
84100		<1%	14	$19.90
84550		<1%	14	$19.00
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	0%	1,040	$0.00
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	0%	31	$0.00
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	0%	60	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	60	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGRAY, KEITH (MANAGING PARTNER)

Same official

Other billing entities under GRAY, KEITH

Full network →

Provider	Location	Paid
Axis Professional Labs LLC	Farmers Branch, TX	$459K
Leannah Investment Partners, LTD	Frisco, TX	$264K
Kingdom Health Laboratory LLC	Dallas, TX	$19K
Global Reach Labs, LLC	Denver, CO	$408.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.